Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of S227928 Alone and with Venetoclax in R/R AML, MDS/AML, or CMML
jRCT2031250133Phase 2Active, not recruiting
- Sponsor
- Servier
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of S227928 in acute myeloid leukemia (AML), acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) and chronic myelomonocytic leukemia (CMML) (2 arms), sponsored by Servier. Primary endpoints: Dose-limiting toxicities of S227928 monotherapy in first treatment cycle, Dose-limiting toxicities of S227928 plus venetoclax in first treatment cycle and 1 more. Started May 2025; status: active, not recruiting.
02
Drugs
S227928
03
Conditions
acute myeloid leukemia (AML)acute myeloid leukemia with myelodysplasia-related changes (AML-MRC)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on jRCT2031250133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250133.